

Geschäftsleitung
Dr. med. Martina Fliser
Dr. med. Martin Holfelder

Fachärzte
Dr. med. Dörte Beier
Carmen Black
Dr. Irena Crnkovic-Mertens
Helene Derksen
Prof. Dr. med. Peter Findeisen
Dr. med. Martina Fliser*
Dr. med.
Gabriele Genthner-Grimm
Roya Karbaf
Dr. med. Anne-Sophie Limbach
MUDr. Hans Jakob Limbach
Dr. med. Hans-Jakob Limbach*
Dr. med. Cyrill Müller
Joachim Singer
Dr. med. Stefan Walch
Fachärzte für
Laboratoriumsmedizin
Prof. Dr. med. Herbert Hof
Dr. med. Klaus Oberdorfer
Fachärzte für Mikrobiologie,
Virologie und Infektions-
epidemiologie / Hygiene
und Umweltmedizin / Labora-
toriumsmedizin
Dr. med. Martin Holfelder*
Fachärzte für Laboratoriums-
medizin / Mikrobiologie,
Virologie und Infektions-
epidemiologie
Dr. med. univ. Ilka Steiner
Fachärztin für Laboratoriums-
medizin / Mikrobiologie, Virolo-
gie und Infektionsepidemio-
logie / Klinische Pharmakologie
Dr. med. Konrad Bode
Dr. med. Jan Kubis
Dr. med.
Torsten Schmidt-Wieland
Sabine Singer
Fachärzte für
Mikrobiologie, Virologie und
Infektionsepidemiologie
Dr. med. Sabine Schütt
Prof. Dr. med.
Constanze Wendt
Fachärztinnen für
Mikrobiologie, Virologie und
Infektionsepidemiologie /
Hygiene und Umweltmedizin
PD Dr. med. Karin Janetzko
Fachärztin für Transfusions-
medizin / Laboratoriums-
medizin

*Ärztliche Leitung

Heidelberg, 14. March 2025

Important safety information on Inhibin B test results

Dear Sir or Madam,

Due to a recent communication from Beckman Coulter GmbH, we would like to inform you about a potential inaccuracy in the determination of Inhibin B in serum for certain reagent batches that were also used in our laboratory.

Situation: The manufacturer Beckman Coulter has determined that incorrectly high values may have been measured when using certain batches for the determination of inhibin B. This error could not be detected by the internal quality controls routinely carried out by us. This error could not be detected by our routine internal quality controls. The average increase in test results was around 15 %, in one reported case even 44 %.

Possible effects: Due to this erroneous increase, patients may have been wrongly subjected to additional diagnostic tests. Inhibin B is generally not used in isolation for diagnostic decisions. Nevertheless, it can play an important role in specific clinical contexts (e.g. reproductive medicine, fertility diagnostics, tumour marker analyses).

Affected test period: 26/10/2024 to 21/02/2025: Enclosed you will find a list of your test orders in this period where the inhibin B values could be affected. Please check these findings in order to take further measures if necessary.

Recommended action: In cases where Inhibin B was relevant for further clinical decisions, we recommend that you carry out a critical review of the findings. If necessary, the parameter can be determined again free of charge for you. The manufacturer Beckman Coulter has now implemented corrective measures so that the test results are reliable again.

If you have any questions about specific patient results or would like a follow-up test, we will of course be happy to help you.

Please contact:

Dr. med. Cyrill Müller

E-Mail: cyrill.mueller@labor-limbach.de

Miriam Reiss

E-Mail: miriam.reiss@labor-limbach.de

We regret the inconvenience caused by this incident and thank you for your understanding and co-operation.

Yours sincerely



Dr. med. Cyrill Müller
Department of Endocrinology
Laboratory Diagnostics
Phone.: +49 6221 / 3432-513



Prof. Dr. med. Peter Findeisen
Medical Director of Laboratory

Enclosure: Laboratory results in the period mentioned